Side-by-side financials for ESPR and AZN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ESPR | AZN |
|---|---|---|
| Market cap | - | $286.27 B |
| US-listed rank | - | #49 |
| Revenue (latest FY) | $403.13M | - |
| Net income (latest FY) | -$22.68M | - |
| Net margin | -5.6% | - |
| SEC filings | 885 | 1,004 |
Full pages: Esperion Therapeutics, Inc. and AstraZeneca PLC, or browse the full rankings.